Exelixis (EXEL) Tops Q3 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. META
2. TSLA
3. IBM
4. TXN
5. MRNA
6. LVS
7. SAP
8. CSX
9. LRCX
10. MRK

Go back to Exelixis (EXEL) Tops Q3 EPS by 5c

Cowen Upgrades Exelixis (EXEL) to Outperform

November 5, 2014 6:58 AM EST

Cowen upgraded Exelixis (NASDAQ: EXEL) from Market Perform to Outperform.

For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.

Shares of Exelixis closed at $1.65 yesterday.

... More

Exelixis, Inc. (EXEL) Reports Top-Line Results From a Phase 2 Trial of Cabozantinib

November 4, 2014 4:21 PM EST

Exelixis, Inc. (NASDAQ: EXEL) today announced positive top-line results from a randomized phase 2 trial of cabozantinib and erlotinib alone or in combination as second- or third-line therapy in patients with stage IV EGFR wild-type non-small cell lung cancer (NSCLC). This trial (Study E1512) is sponsored by the U.S. National Cancer Institute (NCI) through a Cooperative Research and Development Agreement between the Cancer Therapy Evaluation Program (CTEP), Division of Cancer Treatment and Diagnosis, NCI and Exelixis. Study E1512 was designed and is being conducted by the ECOG-ACRIN Cancer Research Group as part of Exelixis... More